We report a case of 29-year-old Japanese female with a history of resection of primary carcinoma of the right breast. After a partial response by chemotherapy with pirarubicin and docetaxel for lung metastasis, the patient developed multiple brain and bone metastases. As the degree of overexpression of human epidermal growth factor receptor-2 (HER2) was (2+), trastuzumab was administered in combination with paclitaxel. Asymptomatic left ventricular (LV) systolic dysfunction evaluated by echocardiography was observed ten weeks after the beginning of the treatment. After two weeks of discontinuation of the therapy, however, LV function showed rapid recovery and the resumed use of trastuzumab did not cause further cardiac deterioration. The pa...
Background: The use of trastuzumab is associated with an increased risk of cardiotoxic events such a...
Objective: To report a case of severe infusion reaction during the first dose of intravenously admin...
Trastuzumab is an effective treatment for patients with metastatic breast cancer (MBC) that overexpr...
We report a case of 29-year-old Japanese female with a history of resection of primary carcinoma of ...
Background: Trastuzumab-related cardiotoxicity has been reported in patients receiving trastuzumab c...
Background: Chemotherapeutic agents directed against human epidermal growth factor receptor 2 (HER-2...
This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, develo...
IMPORTANCE: Trastuzumab is a life-saving therapy but is associated with symptomatic and asymptomatic...
Introduction: Trastuzumab, a recombinant humanized monoclonal antibody, targets the external domain ...
Trastuzumab is a monoclonal antibody effective in treating metastatic breast carcinomas. Cardiotoxic...
© Springer Healthcare Communications 2009Introduction: Although having high clinical efficacy in the...
HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MB...
HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MB...
HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MB...
Abstract Background Trastuzumab-related cardiotoxicity has been reported in patients receiving trast...
Background: The use of trastuzumab is associated with an increased risk of cardiotoxic events such a...
Objective: To report a case of severe infusion reaction during the first dose of intravenously admin...
Trastuzumab is an effective treatment for patients with metastatic breast cancer (MBC) that overexpr...
We report a case of 29-year-old Japanese female with a history of resection of primary carcinoma of ...
Background: Trastuzumab-related cardiotoxicity has been reported in patients receiving trastuzumab c...
Background: Chemotherapeutic agents directed against human epidermal growth factor receptor 2 (HER-2...
This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, develo...
IMPORTANCE: Trastuzumab is a life-saving therapy but is associated with symptomatic and asymptomatic...
Introduction: Trastuzumab, a recombinant humanized monoclonal antibody, targets the external domain ...
Trastuzumab is a monoclonal antibody effective in treating metastatic breast carcinomas. Cardiotoxic...
© Springer Healthcare Communications 2009Introduction: Although having high clinical efficacy in the...
HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MB...
HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MB...
HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MB...
Abstract Background Trastuzumab-related cardiotoxicity has been reported in patients receiving trast...
Background: The use of trastuzumab is associated with an increased risk of cardiotoxic events such a...
Objective: To report a case of severe infusion reaction during the first dose of intravenously admin...
Trastuzumab is an effective treatment for patients with metastatic breast cancer (MBC) that overexpr...